PRESS RELEASE


Clinerion and Datametrix partner to deliver Real World Evidence (RWE) insights from Real World Data (RWD) from Clinerion’s global hospital network.

The partners will deliver an integrated clinical research offer transforming Real World Data (RWD) from the global site and patient network on Clinerion’s Patient Network Explorer into Real World Evidence (RWE) through the use of Datametrix’s analytical capabilities.

Together, Clinerion and Datametrix will power Real World Evidence (RWE) research and bring insights on the realities of clinical practice and outcomes. They will enable Real World Data (RWD) research to investigate differential treatment outcomes in support of optimizing care protocols. This is acutely relevant for field-leading clinicians, hospital management and health policy makers.

Following recent FDA guidance calls for more use of RWD to balance the need for randomized controlled studies, biopharma customers can leverage RWE to inform development strategies, help make development decisions and limit the number of costly, full-scale prospective randomized controlled clinical studies. RWE research can also be used to investigate actual patient pathways and give useful insights to determine better, more effective approaches to care.

The synergy that follows from the combination of Clinerion’s RWD and Datametrix’s analytical capabilities supports pharmaceutical companies with optimization of clinical study design to meet strategic development needs while reflecting real patient populations, where the patients are. It helps pharma customers drive successful recruitment by being able to select sites that see a sufficiently large population of potentially eligible patients; and then also helping those sites directly identify the eligible patients. It also enables improvement in the accuracy of RWD comparative clinical studies by applying statistical models to define the RWD study end points. Clinerion can use their access to RWD data to recruit patient to RWD comparative arms.

“We believe that data collected in an organized and simple manner, then analyzed using the right analytical tools will empower pharmaceutical and biotechnology companies to bring better drugs to market faster,” says Ahmed El Rhali, CEO of Datametrix. “Together, Datametrix and Clinerion can
power Real World Evidence research and bring insights in the realities of clinical practice, which is acutely relevant for pharmaceutical industry, field-leading clinicians, hospital management, healthcare policy makers and, of course, patients.”

“Clinerion and Datametrix are acutely aware that clinical trials are becoming more complex.” says Léon Van Wouwe, Site & Patient Network Director, Clinerion. “And despite global technological advances, the time to get new treatment options to patients and the associated costs are going up. We need to reimagine how pharma sponsors, CROs, investigators and patients engage with another and collaborate to drive successful trial design & delivery. This partnership presents an ‘integrated clinical research offer,’ in which patients, investigators, research sites, pharma and other service providers integrate efforts to unite around one single purpose: to bring together all patients with all the available treatment options that may suit them, and so improve patient outcomes.”

About Clinerion

Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion’s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.

Clinerion website: www.clinerion.com
Clinerion’s Patient Network Explorer: www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer

For more information, please contact:
  Le Vin Chin
  Director, Head of Marketing & Communications
  Clinerion Ltd
  Elisabethenanlage 11, 4051 Basel, Switzerland
  Tel.: +41 61 865 60 54
  media@clinerion.com

About Datametrix AG

Datametrix AG is a Swiss data analysis company founded in 2003. We close the gap between data
and information by bridging science together with data, advanced analytics and expert knowledge to deliver beyond expected results! We shape our services around customers’ business needs to offer them the different way forward in four main area of our expertise:

1. Data analysis, including RWD and RWE
2. Biostatistical analysis
3. HEOR modelling
4. Data management

Unlock your data potential, with the possibility to supplement the primary data collection points with real world insights, choose simple and problem loss data analysis solutions, solid expert knowledge and customer oriented approach.

Datametrix website: [www.datametrix.ch](http://www.datametrix.ch)

For more information, please contact:

Ahmed El Rhali
CEO
Datametrix AG
Faubourg de l’Hopital 3, Neuchâtel, Switzerland
Tel.: +41 32 511 4575
[ahmed@datametrix.ch](mailto:ahmed@datametrix.ch)

Irina El-Ali
COO
Datametrix AG
Faubourg de l’Hopital 3, Neuchâtel, Switzerland
Tel.: +41 32 511 4575
Mobile: +41 79 212 7199
[irina.el-ali@datametrix.ch](mailto:irina.el-ali@datametrix.ch)